Showing results (261-270 of 584) with videos related to

Sort By:
Pageof 59
Acta Psychiatrica Belgica|September 1, 1980
Influence of estrogens on tuberoinfundibular and striatal dopaminergic systems in the ratF Labrie, L Ferland, R Veilleux, et al.
Journal of Steroid Biochemistry|October 1, 1987
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancerC Labrie, L Cusan, M Plante, et al.
British Medical Journal (Clinical Research Ed.)|August 10, 1985
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrationsF Labrie, A Dupont, A Belanger, et al.
Journal of Andrology|November 1, 1989
Normal gonadal functions and fertility after 23 months of treatment of prepubertal male and female dogs with the GnRh agonist [D-Trp6, des-Gly-NH2(10)]GnRH ethylamideD Lacoste, D Dubé, C Trudel, et al.
Molecular and Cellular Endocrinology|July 1, 1983
Rat ovarian epidermal growth factor receptors: characterization and hormonal regulationR St-Arnaud, P Walker, P A Kelly, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1984
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancerF Labrie, A Dupont, A Bélanger, et al.
Microscopy Research and Technique|November 14, 2000
Unique features of the basal cells of human prostate epitheliumM El-Alfy, G Pelletier, L S Hermo, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 1, 1992
Expression of human 17 beta-hydroxysteroid dehydrogenase in mammalian cellsM Dumont, V Luu-The, Y de Launoit, et al.
Endocrinology|March 1, 1992
Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cellsJ Simard, Y de Launoit, D E Haagensen, et al.
Cancer|February 1, 1993
Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapyF Labrie, A Belanger, J Simard, et al.
Pageof 59